Ixekizumab Clinical Trials (2026): 58 Studies for Psoriasis & Plaque Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
58 Ixekizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 27 indications (including Psoriasis & Plaque Psoriasis) and 15,820 total planned enrollment. 27 Phase 3 Ixekizumab trials and 7 Phase 2, 10 Phase 4 are listed. 9 Ixekizumab clinical trials are actively recruiting. Most recent activity: NCT07352566 (Jun 2030).
Ixekizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | ||||||
| P1 | 1 | 5 | 1 | 7 | ||||
| P2 | 1 | 5 | 1 | 7 | ||||
| P2/P3 | 1 | 1 | ||||||
| P3 | 3 | 22 | 1 | 1 | 27 | |||
| P4 | 2 | 6 | 1 | 1 | 10 | |||
| N/A | 3 | 1 | 1 | 5 |
Recruiting Ixekizumab clinical trials (9)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT07443956 | COMBAT-PsACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | N/A | Psoriatic Arthritis (PsA) | 45 | Mar 2026 |
| NCT06398106 | HELIOSProactive TDM Versus Standard Use of Biologics in Psoriasis | P4 | Psoriasis Vulgaris | 210 | Dec 2024 |
| NCT06811558 | Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis | N/A | Over 70-year-old Patients with Psoriasis | 100 | Feb 2025 |
| NCT05503875 | Immunoclassification of Psoriasis: a Strategy for Precision Medicine | N/A | Immunoclassification | 100 | Jan 2023 |
| NCT04537689 | Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis | P4 | Plaque Psoriasis | 40 | Dec 2020 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT06786936 | ELATEEvaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | Psoriatic Arthritis | 50 | Jun 2025 |
| NCT06374979 | Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis | P2/P3 | Guttate Psoriasis | 50 | May 2025 |
Ixekizumab clinical trials by indication
Psoriasis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT06588283 | TOGETHER-PsO | P3 | active not recruiting | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
| NCT04340076 | BeNeBio | P4 | completed | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
| NCT01646177 | UNCOVER-3 | P3 | completed | A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) |
| NCT01597245 | UNCOVER-2 | P3 | completed | A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) |
| NCT03073213 | — | P1 | completed | A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris |
| NCT01474512 | UNCOVER-1 | P3 | completed | A Phase 3 Study in Participants With Moderate to Severe Psoriasis |
| NCT02993471 | — | P1 | completed | A Study of Ixekizumab in Participants With Plaque Psoriasis |
| + 3 more, see All trials below. | ||||
Plaque Psoriasis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04537689 | — | P4 | recruiting | Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis |
| NCT06945107 | — | P3 | active not recruiting | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy |
| NCT05042635 | — | N/A | unknown | Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine |
| NCT05855967 | LY2439821 | P4 | completed | A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India |
| NCT03073200 | Ixora-peds | P3 | completed | Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis |
| NCT03364309 | LY2439821 | P3 | completed | A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis |
| NCT03573323 | IXORA-R | P4 | completed | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis |
| NCT02634801 | LY2439821 | P3 | completed | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment |
| + 3 more, see All trials below. | ||||
Psoriatic Arthritis (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06786936 | ELATE | N/A | recruiting | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms |
| NCT06588296 | TOGETHER-PsA | P3 | completed | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
| NCT04610476 | — | P3 | unknown | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
| NCT03151551 | SPIRIT-H2H | P4 | completed | A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis |
| NCT02349295 | SPIRIT-P2 | P3 | completed | A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis |
| NCT02584855 | SPIRIT P3 | P3 | completed | A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis |
Healthy (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04259346 | — | P1 | completed | A Study of Two Formulations of Ixekizumab in Healthy Participants |
| NCT03848403 | — | P1 | terminated | Study of Ixekizumab in Healthy Participants |
| NCT03848416 | — | P1 | completed | A Study of Ixekizumab in Healthy Participants |
| NCT02543918 | LY2439821 | P1 | completed | A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants |
Spondyloarthritis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04285229 | LY2439821 | P3 | completed | A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis |
| NCT02696798 | COAST-W | P3 | completed | A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis |
| NCT02696785 | COAST-V | P3 | completed | A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis |
Axial Spondyloarthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03129100 | LY2439821 | P3 | completed | A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis |
| NCT02757352 | COAST-X | P3 | completed | A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis |
Psoriatic Arthritis (PsA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07443956 | COMBAT-PsA | N/A | recruiting | Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07200986 | — | P1 | active not recruiting | Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects |
Guttate Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06374979 | — | P2/P3 | not yet recruiting | Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis |
Over 70-year-old Patients with Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06811558 | — | N/A | not yet recruiting | Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis |
Psoriasis Vulgaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06398106 | HELIOS | P4 | recruiting | Proactive TDM Versus Standard Use of Biologics in Psoriasis |
Immunoclassification (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05503875 | — | N/A | recruiting | Immunoclassification of Psoriasis: a Strategy for Precision Medicine |
Type1 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04589325 | I-DIT | P2 | active not recruiting | Ixekizumab Diabetes Intervention Trial (I-DIT) |
Uveitis, Posterior (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06085079 | — | P4 | unknown | Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study |
Rheumatoid Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05080218 | COVER | P4 | completed | COVID-19 VaccinE Response in Rheumatology Patients |
Major Depressive Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04979910 | — | P2 | completed | Targeting IL-17A for Treatment-Resistant Depression |
Lichen Planus Scalp (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05030415 | — | Early P1 | completed | Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris |
Juvenile Psoriatic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04527380 | LY2439821 | P3 | active not recruiting | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
Covid19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04724629 | STRUCK | P3 | completed | Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) |
Generalized Pustular Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03942042 | LY2439821 | P4 | completed | A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis |
Pityriasis Rubra Pilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03485976 | PRP | P2 | completed | Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP) |
Bullous Pemphigoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03099538 | — | P2 | completed | Ixekizumab in the Treatment of Bullous Pemphigoid |
Pyoderma Gangrenosum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03137160 | — | P2 | completed | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum |
Genital Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02718898 | IXORA-Q | P3 | completed | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis |
Spondylitis, Ankylosing (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01870284 | SPIRIT A1 | P3 | withdrawn | Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) |
Psoriasis, Arthritic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01695239 | SPIRIT-P1 | P3 | completed | A Study of Ixekizumab in Participants With Active Psoriatic Arthritis |
Ixekizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| HELIOS | NCT06398106 | P4 | recruiting | Psoriasis Vulgaris | 210 | — |
| BeNeBio | NCT04340076 | P4 | completed | Psoriasis | 244 | PMID 34656148 |
| LY2439821 | NCT05855967 | P4 | completed | Plaque Psoriasis | 250 | — |
| COVER | NCT05080218 | P4 | completed | Rheumatoid Arthritis | 841 | — |
| LY2439821 | NCT03942042 | P4 | completed | Generalized Pustular Psoriasis | 12 | PMID 34967916 |
| IXORA-R | NCT03573323 | P4 | completed | Plaque Psoriasis | 1,027 | PMID 38332436 |
| SPIRIT-H2H | NCT03151551 | P4 | completed | Psoriatic Arthritis | 566 | PMID 33200394 |
| LY2439821 | NCT04527380 | P3 | active not recruiting | Juvenile Psoriatic Arthritis | 101 | PMID 41785908 |
| TOGETHER-PsO | NCT06588283 | P3 | active not recruiting | Psoriasis | 250 | — |
| TOGETHER-PsA | NCT06588296 | P3 | completed | Psoriatic Arthritis | 279 | PMID 41903163 |
| LY2439821 | NCT04285229 | P3 | completed | Spondyloarthritis | 147 | PMID 41495585 |
| STRUCK | NCT04724629 | P3 | completed | Covid19 | 60 | — |
| LY2439821 | NCT03129100 | P3 | completed | Axial Spondyloarthritis | 773 | PMID 35853675 |
| Ixora-peds | NCT03073200 | P3 | completed | Plaque Psoriasis | 201 | PMID 35416908 |
| LY2439821 | NCT03364309 | P3 | completed | Plaque Psoriasis | 438 | PMID 39347926 |
| UNCOVER-3 | NCT01646177 | P3 | completed | Psoriasis | 1,346 | PMID 27910156 |
| SPIRIT-P2 | NCT02349295 | P3 | completed | Psoriatic Arthritis | 363 | PMID 33278016 |
| UNCOVER-2 | NCT01597245 | P3 | completed | Psoriasis | 1,224 | PMID 30465321 |
| COAST-X | NCT02757352 | P3 | completed | Axial Spondyloarthritis | 303 | PMID 33044756 |
| COAST-W | NCT02696798 | P3 | completed | Spondyloarthritis | 316 | PMID 34853086 |
| SPIRIT P3 | NCT02584855 | P3 | completed | Psoriatic Arthritis | 394 | PMID 35393269 |
| COAST-V | NCT02696785 | P3 | completed | Spondyloarthritis | 341 | PMID 39509838 |
| UNCOVER-1 | NCT01474512 | P3 | completed | Psoriasis | 1,296 | PMID 35279805 |
| SPIRIT A1 | NCT01870284 | P3 | withdrawn | Spondylitis, Ankylosing | 0 | — |
| IXORA-Q | NCT02718898 | P3 | completed | Genital Psoriasis | 149 | — |
| LY2439821 | NCT02634801 | P3 | completed | Plaque Psoriasis | 162 | PMID 31376153 |
| IXORA-S | NCT02561806 | P3 | completed | Plaque Psoriasis | 302 | PMID 32415575 |
| SPIRIT-P1 | NCT01695239 | P3 | completed | Psoriasis, Arthritic | 417 | PMID 29247148 |
| UNCOVER-J | NCT01624233 | P3 | completed | Psoriasis | 91 | PMID 25355284 |
| IXORA-P | NCT02513550 | P3 | completed | Plaque Psoriasis | 1,257 | — |
| LY2439821 | NCT02387801 | P3 | completed | Psoriasis | 12 | PMID 29785237 |
| UNCOVER-A | NCT01777191 | P3 | completed | Plaque Psoriasis | 204 | PMID 27500949 |
| I-DIT | NCT04589325 | P2 | active not recruiting | Type1 Diabetes Mellitus | 127 | PMID 41224288 |
| PRP | NCT03485976 | P2 | completed | Pityriasis Rubra Pilaris | 12 | PMID 32293641 |
Terminated and withdrawn Ixekizumab trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03848403terminatedStudy of Ixekizumab in Healthy Participants
- NCT01870284withdrawnStudy of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
All Ixekizumab trials (58)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT07443956 | COMBAT-PsA | Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | N/A | recruiting | 45 | NHS Greater Glasgow and Clyde | Mar 2026 |
| NCT04527380 | LY2439821 | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | P3 | active not recruiting | 101 | Eli Lilly and Company | Apr 2021 |
| NCT06398106 | HELIOS | Proactive TDM Versus Standard Use of Biologics in Psoriasis | P4 | recruiting | 210 | University Hospital, Ghent | Dec 2024 |
| NCT06811558 | Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis | N/A | not yet recruiting | 100 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Feb 2025 | |
| NCT05503875 | Immunoclassification of Psoriasis: a Strategy for Precision Medicine | N/A | recruiting | 100 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jan 2023 | |
| NCT04589325 | I-DIT | Ixekizumab Diabetes Intervention Trial (I-DIT) | P2 | active not recruiting | 127 | Göteborg University | Nov 2022 |
| NCT04537689 | Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis | P4 | recruiting | 40 | Singapore General Hospital | Dec 2020 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT06786936 | ELATE | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | recruiting | 50 | NHS Greater Glasgow and Clyde | Jun 2025 |
| NCT06945107 | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy | P3 | active not recruiting | 308 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | May 2025 | |
| NCT06374979 | Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis | P2/P3 | not yet recruiting | 50 | Second Affiliated Hospital, School of Medicine, Zhejiang University | May 2025 | |
| NCT06588283 | TOGETHER-PsO | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | P3 | active not recruiting | 250 | Eli Lilly and Company | Sep 2024 |
| NCT06588296 | TOGETHER-PsA | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | P3 | completed | 279 | Eli Lilly and Company | Sep 2024 |
| NCT07200986 | Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects | P1 | active not recruiting | 218 | Celltrion | Sep 2025 | |
| NCT04610476 | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis | P3 | unknown | 270 | University of Erlangen-Nürnberg Medical School | Oct 2020 | |
| NCT04340076 | BeNeBio | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | P4 | completed | 244 | Radboud University Medical Center | Aug 2020 |
| NCT06085079 | Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study | P4 | unknown | 20 | Massachusetts Eye Research and Surgery Institution | Jun 2022 | |
| NCT05042635 | Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine | N/A | unknown | 90 | Shanghai Yueyang Integrated Medicine Hospital | Oct 2021 | |
| NCT05855967 | LY2439821 | A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India | P4 | completed | 250 | Eli Lilly and Company | Jun 2023 |
| NCT05080218 | COVER | COVID-19 VaccinE Response in Rheumatology Patients | P4 | completed | 841 | Jeffrey Curtis | Nov 2021 |
| NCT04979910 | Targeting IL-17A for Treatment-Resistant Depression | P2 | completed | 7 | Icahn School of Medicine at Mount Sinai | Aug 2021 | |
| NCT05030415 | Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris | Early P1 | completed | 9 | University of New Mexico | Aug 2021 | |
| NCT04285229 | LY2439821 | A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis | P3 | completed | 147 | Eli Lilly and Company | Apr 2020 |
| NCT04724629 | STRUCK | Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) | P3 | completed | 60 | University of Sao Paulo | Jan 2021 |
| NCT03129100 | LY2439821 | A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis | P3 | completed | 773 | Eli Lilly and Company | May 2017 |
| NCT03073200 | Ixora-peds | Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis | P3 | completed | 201 | Eli Lilly and Company | Mar 2017 |
| NCT04259346 | A Study of Two Formulations of Ixekizumab in Healthy Participants | P1 | completed | 245 | Eli Lilly and Company | Feb 2020 | |
| NCT03942042 | LY2439821 | A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | P4 | completed | 12 | Eli Lilly and Company | Jul 2019 |
| NCT03364309 | LY2439821 | A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis | P3 | completed | 438 | Eli Lilly and Company | Apr 2018 |
| NCT03485976 | PRP | Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP) | P2 | completed | 12 | Oregon Health and Science University | May 2018 |
| NCT03573323 | IXORA-R | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis | P4 | completed | 1,027 | Eli Lilly and Company | Nov 2018 |
| NCT03151551 | SPIRIT-H2H | A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis | P4 | completed | 566 | Eli Lilly and Company | Aug 2017 |
| NCT01646177 | UNCOVER-3 | A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) | P3 | completed | 1,346 | Eli Lilly and Company | Jul 2012 |
| NCT03848403 | Study of Ixekizumab in Healthy Participants | P1 | terminated | 70 | Eli Lilly and Company | Jan 2019 | |
| NCT02349295 | SPIRIT-P2 | A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | P3 | completed | 363 | Eli Lilly and Company | Dec 2014 |
| NCT01597245 | UNCOVER-2 | A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) | P3 | completed | 1,224 | Eli Lilly and Company | May 2012 |
| NCT03848416 | A Study of Ixekizumab in Healthy Participants | P1 | completed | 99 | Eli Lilly and Company | Jan 2019 | |
| NCT03099538 | Ixekizumab in the Treatment of Bullous Pemphigoid | P2 | completed | 4 | Mayo Clinic | Aug 2017 | |
| NCT03073213 | A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris | P1 | completed | 32 | Eli Lilly and Company | Apr 2017 | |
| NCT02757352 | COAST-X | A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis | P3 | completed | 303 | Eli Lilly and Company | Aug 2016 |
| NCT02696798 | COAST-W | A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis | P3 | completed | 316 | Eli Lilly and Company | Apr 2016 |
| NCT02584855 | SPIRIT P3 | A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | P3 | completed | 394 | Eli Lilly and Company | Sep 2015 |
| NCT02696785 | COAST-V | A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis | P3 | completed | 341 | Eli Lilly and Company | May 2016 |
| NCT01474512 | UNCOVER-1 | A Phase 3 Study in Participants With Moderate to Severe Psoriasis | P3 | completed | 1,296 | Eli Lilly and Company | Nov 2011 |
| NCT03137160 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | P2 | completed | 4 | Ohio State University | May 2017 | |
| NCT01870284 | SPIRIT A1 | Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) | P3 | withdrawn | 0 | Eli Lilly and Company | Jul 2014 |
| NCT02718898 | IXORA-Q | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis | P3 | completed | 149 | Eli Lilly and Company | Apr 2016 |
| NCT02993471 | A Study of Ixekizumab in Participants With Plaque Psoriasis | P1 | completed | 28 | Eli Lilly and Company | Dec 2016 | |
| NCT02634801 | LY2439821 | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment | P3 | completed | 162 | Eli Lilly and Company | Jan 2016 |
| NCT02561806 | IXORA-S | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis | P3 | completed | 302 | Eli Lilly and Company | Oct 2015 |
| NCT01695239 | SPIRIT-P1 | A Study of Ixekizumab in Participants With Active Psoriatic Arthritis | P3 | completed | 417 | Eli Lilly and Company | Dec 2012 |
| NCT01624233 | UNCOVER-J | A Study in Japanese Participants With Moderate-to-Severe Psoriasis | P3 | completed | 91 | Eli Lilly and Company | Jun 2012 |
| NCT02513550 | IXORA-P | A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis | P3 | completed | 1,257 | Eli Lilly and Company | Aug 2015 |
| NCT02387801 | LY2439821 | A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis | P3 | completed | 12 | Eli Lilly and Company | Apr 2015 |
| NCT01107457 | A Study in Participants With Moderate to Severe Psoriasis | P2 | completed | 142 | Eli Lilly and Company | Apr 2010 | |
| NCT02543918 | LY2439821 | A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants | P1 | completed | 84 | Eli Lilly and Company | Sep 2015 |
| NCT01777191 | UNCOVER-A | Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis | P3 | completed | 204 | Eli Lilly and Company | Mar 2013 |
Ixekizumab clinical trials: frequently asked questions
- How many Ixekizumab clinical trials are there?
- 58 Ixekizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 39 are marked completed.
- Are Ixekizumab clinical trials recruiting in 2026?
- Yes — 5 Ixekizumab trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ixekizumab being studied for?
- Ixekizumab is being studied for Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Healthy, Spondyloarthritis and 38 more. The trials are grouped by indication on this page.
- What phase is Ixekizumab in?
- Ixekizumab clinical trials span 10 Phase 4, 27 Phase 3, 7 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ixekizumab clinical trials?
- The lead sponsor across the most Ixekizumab trials is Eli Lilly and Company, with 20 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ixekizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: